Published online Oct 16, 2021. doi: 10.12998/wjcc.v9.i29.8749
Peer-review started: January 29, 2021
First decision: May 2, 2021
Revised: May 20, 2021
Accepted: September 8, 2021
Article in press: September 8, 2021
Published online: October 16, 2021
Processing time: 259 Days and 5.1 Hours
The effect of preexisting chronic hepatitis C infection in coronavirus disease 2019 (COVID-19) patients has not been studied. Initial reports have suggested that COVID-19 patients with hepatitis C virus (HCV) are at increased risk for poor outcomes especially if accompanied by other risk factors such as advanced age and hypertension.
We have found that hepatitis C is associated with increased in-hospital mortality in patients hospitalized with COVID-19.
We aimed at assessing the relationship between in-hospital mortality with other predictors of poor outcomes in the presence or absence of baseline liver dysfunction or COVID-19 induced acute liver injury.
We reviewed retrospectively the medical charts of patients with COVID-19 admission and the laboratory parameter in patients with and without history of HCV infection. Patients were then divided into two groups based on the presence or absence of a history of HCV and their demographic, clinical, laboratory variables, and outcomes were compared. The primary endpoint of our study was in-hospital mortality.
Multivariate cox-regression model for liver profile revealed that aspartate aminotransferase/ alanine aminotransferase ratio, Fib-4 score, and HCV were predictors of in-hospital mortality. After propensity score matching HCV was the only predictor of mortality in the multivariate cox-regression model. 2-log likelihood ratio was done to compare different diagnostic models and it was found that a model including HCV add a predictive value to clinical and laboratory parameters.
HCV infection accentuated severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) viral virulence in our study and had a strong association with in-hospital mortality irrespective of baseline co-morbidities, admission laboratory variables, or COVID-19-induced liver injury. The mechanisms involved may be related to extra-hepatic effects of HCV, baseline cytokine-mediated pro-inflammation, and endothelial dysfunction. Understanding of these mechanisms may help in better characterization of the disease and investigating possible therapeutic options in this subgroup of patients.
COVID-19 is significantly heterogeneous. Predictors of Mortality are numerous and association of baseline risk and co-morbidities are still developing. Based on an observation of HCV association with increased risk in our institution we sought to investigate the relationship between HCV and COVID-19 mortality